Allied Market Research
Loading...
0
New
New
2021
Pharmacovigilance Outsourcing Market

Pharmacovigilance Outsourcing Market by Type (Adverse Drug Reaction Capture (ADR), Case Processing, Reporting and Submission, Report Publishing, Quality Check, Risk Management, Knowledge Management, and Enabling Architecture), Service Provider (Contract Research Organizations and Business Processing Outsourcing), and End User (Pharmaceutical Industry, Research Organizations, and Others): Global Opportunity Analysis and Industry Forecast, 2021–2030.

A10915
Pages: 278
Jul 2021 | 766 Views
   
Author(s) : Sushant Terdale , Onkar Sumant
Tables: 119
Charts: 51
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Pharmacovigilance Outsourcing Market

Request Now !

Pharmacovigilance Outsourcing Market Overview 2030

The global pharmacovigilance outsourcing market size was valued at $2,489.10 million in 2020 and is projected to reach $9,654.10 million by 2030 registering a CAGR of 14.60% from 2021 to 2030.

Transfer of drug safety operations and processes by a life science company to a third-party service provider is known as pharmacovigilance outsourcing. Collecting ADR data, case processing, developing risk management plans and risk evaluation mitigation strategies, and preparing and submitting aggregate and expedited pharmacovigilance reports are all routine pharmacovigilance activities that are commonly outsourced.

Pharmacovigilance-Outsourcing-Market-2021-2030

Get more information on this report : Request Sample Pages

Rise in preference for outsourcing services, owing to benefits associated with pharmacovigilance outsourcing services such as cost-effective services and low operational expenses is one of the major factors that boost growth of the pharmacovigilance outsourcing market. In addition, increase in adverse drug reactions and drug toxicity associated with pharmaceutical products further fuel the market growth. Furthermore, high profile drug recalls due to safety concerns also rises the need for medical information by regulatory authorities, which anticipated to drive growth of the market. However, risk associated with data security and shortage of skilled professionals for maintaining compliance, which hampers growth of the market. In contrast, growth opportunities in emerging markets, owing to availability of cost-effective pharmacovigilance outsourcing services provided by leading CROs and BPOs in emerging economies create lucrative opportunities for the pharmacovigilance outsourcing market. 

The outbreak of COVID-19 has disrupted workflows in the health care sector across the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of health care. However, there has also been a positive effect and surge in demand for various medical services, including pharmacovigilance outsourcings. Medical monitoring and safety reporting are essential as several potential therapies are being used in the treatment of coronavirus-induced infection. Medications such as Lopinavir/Ritonavir, hydroxychloroquine (HCQ), and Remdesivir are being repurposed to treat coronavirus infection. The chances of suspected adverse drug reactions for some of these medicines have already been submitted to individual case safety reports database named VigiBase, managed by Uppsala Monitoring Centre (UMC). Thus, rise in incidences of adverse drug reactions is anticipated to accelerate demand for pharmacovigilance services amid such pandemics. Hence, the outbreak of COVID-19 has positively impacted the pharmacovigilance outsourcing market. 

Pharmacovigilance Outsourcing Market Segmentation  

The global pharmacovigilance outsourcing market is segmented on the basis of type, service providers, end user, and region. By type, the market is divided into adverse drug reaction capture (ADR), case processing, reporting and submission, report publishing, quality check, risk management, knowledge management, and enabling architecture. On the basis of service provider, it is segmented into contract research organization and business processing outsourcing. By end user, it is divided into pharmaceutical industry, research organization, and others. The others segment is further divided into regulatory organization and hospitals. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Segment Review

Based on type, the case processing segment dominated the global market in 2020, and is anticipated to continue this trend during the forecast period. The key factors such as continuous increase in cases from various sources resulting from research and development and rise in need to ensure quality of data.

Pharmacovigilance Outsourcing Market
By Product

Your browser does not support the canvas element.

Case Processing segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Based on service provider, contract research organization segment dominated the global market in 2020, and is expected to remain dominant throughout the forecast period. This is attributed to various advantages of contract research organization such as cost-effective services, time saving processes, advanced technological needs, and evolving and complex regulatory requirements.

Based on end user, the pharmaceutical industry segment held the largest market share in 2020, and is expected to remain dominant throughout the forecast period, owing to increase in adoption of outsourcing services by the pharmaceutical industry to avoid high upfront investments and fixed overhead costs, increase resource flexibility, and secure additional capacity.

Pharmacovigilance Outsourcing Market
By Application

Your browser does not support the canvas element.

Pharmaceutical industry segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

Snapshot of the Asia-Pacific Pharmacovigilance Outsourcing Market  

Asia-Pacific offers profitable opportunities for key players operating in the pharmacovigilance outsourcing market and is expected to register fastest growth rate during the forecast period, owing to economic development and low operating costs. The major driving factors for the market growth in this region include rise in focus in biopharmaceutical R&D, huge production of drugs, and surge in prevalence of cancer. In addition, strict regulations for reporting adverse drug reactions, coupled with large number of companies offering pharmacovigilance outsourcing services across the region. Furthermore, increase in funding for clinical trials further propel the regional pharmacovigilance outsourcing market growth.

Pharmacovigilance Outsourcing Market
By By Region

2030
North America 
Europe
Asia-pacific
Lamea

North America is expected to experience growth at the highest rate, registering a CAGR of 13.20 % during the forecast period.

Get more information on this report : Request Sample Pages

The key pharmacovigilance outsourcing market players profiled in the report include Accenture PLC., Bioclinica, Capgemini (IGate Corporation), Cognizant Technology Solutions Corporation, Ergomed Plc., Genpact Limited, International Business Machines Corporation, Icon Plc., IQVIA Holdings Inc. (Clintec), and Labcorp Drug Development (Covance).

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the global pharmacovigilance outsourcing market along with the current trends and future estimations to explain the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the pharmacovigilance outsourcing market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2028 is provided to enable the stakeholders to capitalize on the prevailing pharmacovigilance outsourcing market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the application and services of pharmacovigilance outsourcing used across the globe.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

Key Market Segments

By Type

  • Adverse Drug Reaction Capture (ADR)
  • Case Processing
  • Reporting and Submission
  • Report Publishing
  • Quality Check
  • Risk Management
  • Knowledge Management
  • Enabling Architecture  

By Service Provider

  • Contract Research Organization
  • Business Processing Outsourcing 

By End User

  • Pharmaceutical Industry
  • Research Organization
  • Others  

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China 
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Increase in preferences for outsourcing services
3.5.1.2.Rise in adverse drug reactions and drug toxicity
3.5.1.3.High profile drug recalls

3.5.2.Restraints

3.5.2.1.Risk associated with data security
3.5.2.2.Dearth of skilled professionals

3.5.3.Opportunities

3.5.3.1.Growth opportunities in emerging markets

3.5.4.Impact analysis

3.6.COVID-19 Impact analysis on the pharmacovigilance outsourcing market

CHAPTER 4:PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Adverse Drug Reaction Capture (ADR)

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Case Processing

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country

4.4.Reporting and Submission

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

4.5.Report Publishing

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country

4.6.Quality Check

4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country

4.7.Risk Management

4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast, by region
4.7.3.Market analysis, by country

4.8.Knowledge Management

4.8.1.Key market trends, growth factors, and opportunities
4.8.2.Market size and forecast, by region
4.8.3.Market analysis, by country

4.9.Enabling Architecture

4.9.1.Key market trends, growth factors, and opportunities
4.9.2.Market size and forecast, by region
4.9.3.Market analysis, by country

CHAPTER 5:PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER

5.1.Overview

5.1.1.Market size and forecast

5.2.Contract Research Organizations

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.2.3.Market size and forecast, by end user

5.3.Business Processing Outsourcing

5.3.1.Market size and forecast
5.3.2.Market analysis, by country
5.3.3.Market size and forecast, by end user

CHAPTER 6:PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER

6.1.Overview

6.1.1.Market size and forecast

6.2.Pharmaceutical Industry

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Research Organization

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

6.4.Others

6.4.1.Market size and forecast
6.4.2.Market analysis, by country

CHAPTER 7:PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country

7.2.2.1.U.S.

7.2.2.1.1.U.S. pharmacovigilance outsourcing market, by type
7.2.2.1.2.U.S. pharmacovigilance outsourcing market, by service provider
7.2.2.1.3.U.S. pharmacovigilance outsourcing market, by end user

7.2.2.2.Canada

7.2.2.2.1.Canada pharmacovigilance outsourcing market, by type
7.2.2.2.2.Canada pharmacovigilance outsourcing market, by service provider
7.2.2.2.3.Canada pharmacovigilance outsourcing market, by end user

7.2.2.3.Mexico

7.2.2.3.1.Mexico pharmacovigilance outsourcing market, by type
7.2.2.3.2.Mexico pharmacovigilance outsourcing market, by service provider
7.2.2.3.3.Mexico pharmacovigilance outsourcing market, by end user

7.2.3.North America market size and forecast, by type
7.2.4.North America market size and forecast, by service provider
7.2.5.North America market size and forecast, by end user

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country

7.3.2.1.Germany

7.3.2.1.1.Germany pharmacovigilance outsourcing market, by type
7.3.2.1.2.Germany pharmacovigilance outsourcing market, by service provider
7.3.2.1.3.Germany pharmacovigilance outsourcing market, by end user

7.3.2.2.France

7.3.2.2.1.France pharmacovigilance outsourcing market, by type
7.3.2.2.2.France pharmacovigilance outsourcing market, by service provider
7.3.2.2.3.France pharmacovigilance outsourcing market, by end user

7.3.2.3.UK

7.3.2.3.1.UK pharmacovigilance outsourcing market, by type
7.3.2.3.2.UK pharmacovigilance outsourcing market, by service provider
7.3.2.3.3.UK pharmacovigilance outsourcing market, by end user

7.3.2.4.Italy

7.3.2.4.1.Italy pharmacovigilance outsourcing market, by type
7.3.2.4.2.Italy pharmacovigilance outsourcing market, by service provider
7.3.2.4.3.Italy pharmacovigilance outsourcing market, by end user

7.3.2.5.Spain

7.3.2.5.1.Spain pharmacovigilance outsourcing market, by type
7.3.2.5.2.Spain pharmacovigilance outsourcing market, by service provider
7.3.2.5.3.Spain pharmacovigilance outsourcing market, by end user

7.3.2.6.Rest of Europe

7.3.2.6.1.Rest of Europe pharmacovigilance outsourcing market, by type
7.3.2.6.2.Rest of Europe pharmacovigilance outsourcing market, by service provider
7.3.2.6.3.Rest of Europe pharmacovigilance outsourcing market, by end user

7.3.3.Europe market size and forecast, by type
7.3.4.Europe market size and forecast, by service provider
7.3.5.Europe market size and forecast, by end user

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country

7.4.2.1.Japan

7.4.2.1.1.Japan pharmacovigilance outsourcing market, by type
7.4.2.1.2.Japan pharmacovigilance outsourcing market, by service provider
7.4.2.1.3.Japan pharmacovigilance outsourcing market, by end user

7.4.2.2.China

7.4.2.2.1.China pharmacovigilance outsourcing market, by type
7.4.2.2.2.China pharmacovigilance outsourcing market, by service provider
7.4.2.2.3.China pharmacovigilance outsourcing market, by end user

7.4.2.3.Australia

7.4.2.3.1.Australia pharmacovigilance outsourcing market, by type
7.4.2.3.2.Australia pharmacovigilance outsourcing market, by service provider
7.4.2.3.3.Australia pharmacovigilance outsourcing market, by end user

7.4.2.4.India

7.4.2.4.1.India pharmacovigilance outsourcing market, by type
7.4.2.4.2.India pharmacovigilance outsourcing market, by service provider
7.4.2.4.3.India pharmacovigilance outsourcing market, by end user

7.4.2.5.South Korea

7.4.2.5.1.South Korea pharmacovigilance outsourcing market, by Type
7.4.2.5.2.South Korea pharmacovigilance outsourcing market, by service provider
7.4.2.5.3.South Korea pharmacovigilance outsourcing market, by end user

7.4.2.6.Rest of Asia-Pacific

7.4.2.6.1.Rest of Asia-Pacific pharmacovigilance outsourcing market, by type
7.4.2.6.2.Rest of Asia-Pacific pharmacovigilance outsourcing market, by service provider
7.4.2.6.3.Rest of Asia-Pacific pharmacovigilance outsourcing market, by end user

7.4.3.Asia-Pacific market size and forecast, by type
7.4.4.Asia-Pacific market size and forecast, by service provider
7.4.5.Asia-Pacific market size and forecast, by end user

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country

7.5.2.1.Brazil

7.5.2.1.1.Brazil pharmacovigilance outsourcing market, by type
7.5.2.1.2.Brazil pharmacovigilance outsourcing market, by service provider
7.5.2.1.3.Brazil pharmacovigilance outsourcing market, by end user

7.5.2.2.Saudi Arabia

7.5.2.2.1.Saudi Arabia pharmacovigilance outsourcing market, by type
7.5.2.2.2.Saudi Arabia pharmacovigilance outsourcing market, by service provider
7.5.2.2.3.Saudi Arabia pharmacovigilance outsourcing market, by end user

7.5.2.3.South Africa

7.5.2.3.1.South Africa pharmacovigilance outsourcing market, by type
7.5.2.3.2.South Africa pharmacovigilance outsourcing market, by service provider
7.5.2.3.3.South Africa pharmacovigilance outsourcing market, by end user

7.5.2.4.Rest of LAMEA

7.5.2.4.1.Rest of LAMEA pharmacovigilance outsourcing market, by type
7.5.2.4.2.Rest of LAMEA pharmacovigilance outsourcing market, by service provider
7.5.2.4.3.Rest of LAMEA pharmacovigilance outsourcing market, by end user

7.5.3.LAMEA market size and forecast, by type
7.5.4.LAMEA market size and forecast, by service provider
7.5.5.LAMEA market size and forecast, by end user

CHAPTER 8:COMPANY PROFILES

8.1.ACCENTURE PLC.

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments

8.2.BIOCLINICA INC.

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Key strategic moves and developments

8.3.CAPGEMINI (IGATE CORPORATION)

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance

8.4.COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance

8.5.ERGOMED PLC.

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments

8.6.GENPACT LIMITED

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance

8.7.INTERNATIONAL BUSINESS MACHINES CORPORATION

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance

8.8.ICON PLC

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments

8.9.IQVIA HOLDINGS INC.(CLINTEC)

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments

8.10.LABCORP DRUG DEVELOPMENT (COVANCE)

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020–2030($MILLION)
TABLE 02.ADVERSE DRUG REACTION CAPTURE (ADR) PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 03.CASE PROCESSING PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020–2030($MILLION)
TABLE 04.REPORTING AND SUBMISSION PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020–2030($MILLION)
TABLE 05.REPORT PUBLISHING PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020–2030($MILLION)
TABLE 06.QUALITY CHECK PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020–2030($MILLION)
TABLE 07.RISK MANAGEMENT PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020–2030($MILLION)
TABLE 08.KNOWLEDGE MANAGEMENT PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020–2030($MILLION)
TABLE 09.ENABLING ARCHITECTURE PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020–2030($MILLION)
TABLE 10.PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020–2030($MILLION)
TABLE 11.CONTRACT RESEARCH ORGANIZATIONS PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020–2030($MILLION)
TABLE 12.CONTRACT RESEARCH ORGANIZATION PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 13.BUSINESS PROCESSING OUTSOURCING PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020–2030($MILLION)
TABLE 14.BUSINESS PROCESSING OUTSOURCING PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 15.PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020–2030($MILLION)
TABLE 16.PHARMACEUTICAL INDUSTRY PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020–2030($MILLION)
TABLE 17.RESEARCH ORGANIZATION PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020–2030($MILLION)
TABLE 18.OTHERS PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020–2030($MILLION)
TABLE 19.PHARMACOVIGILANCE OUTSOURCING MARKET, BY REGION, 2020–2030($MILLION)
TABLE 20.NORTH AMERICA PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 21.U.S. PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 22.U.S. PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020–2030 ($MILLION)
TABLE 23.U.S. PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 24.CANADA PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 25.CANADA PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020–2030 ($MILLION)
TABLE 26.CANADA PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 27.MEXICO PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 28.MEXICO PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020–2030 ($MILLION)
TABLE 29.MEXICO PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 30.NORTH AMERICA PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 31.NORTH AMERICA PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020–2030 ($MILLION)
TABLE 32.NORTH AMERICA PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 33.EUROPE PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 34.GERMANY PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 35.GERMANY PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020–2030($MILLION)
TABLE 36.GERMANY PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 37.FRANCE PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 38.FRANCE PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020–2030 ($MILLION)
TABLE 39.FRANCE PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 40.UK PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 41.UK PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020–2030 ($MILLION)
TABLE 42.UK PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 43.ITALY PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 44.ITALY PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020–2030 ($MILLION)
TABLE 45.ITALY PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 46.SPAIN PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 47.SPAIN PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020–2030 ($MILLION)
TABLE 48.SPAIN PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 49.REST OF EUROPE PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 50.REST OF EUROPE PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020–2030 ($MILLION)
TABLE 51.REST OF EUROPE PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 52.EUROPE PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 53.EUROPE PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020–2030 ($MILLION)
TABLE 54.EUROPE PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 55.ASIA-PACIFIC PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 56.JAPAN PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 57.JAPAN PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020–2030 ($MILLION)
TABLE 58.JAPAN PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 59.CHINA PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 60.CHINA PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020–2030 ($MILLION)
TABLE 61.CHINA PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 62.AUSTRALIA PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 63.AUSTRALIA PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020–2030 ($MILLION)
TABLE 64.AUSTRALIA PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 65.INDIA PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 66.INDIA PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020–2030 ($MILLION)
TABLE 67.INDIA PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 68.SOUTH KOREA PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 69.SOUTH KOREA PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020–2030 ($MILLION)
TABLE 70.SOUTH KOREA PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 71.REST OF ASIA-PACIFIC PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 72.REST OF ASIA-PACIFIC PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020–2030 ($MILLION)
TABLE 73.REST OF ASIA-PACIFIC PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 74.ASIA-PACIFIC PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 75.ASIA-PACIFIC PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020–2030 ($MILLION)
TABLE 76.ASIA-PACIFIC PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 77.LAMEA PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 78.BRAZIL PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 79.BRAZIL PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020–2030 ($MILLION)
TABLE 80.BRAZIL PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 81.SAUDI ARABIA PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 82.SAUDI ARABIA PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020–2030 ($MILLION)
TABLE 83.SAUDI ARABIA PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 84.SOUTH AFRICA PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 85.SOUTH AFRICA PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020–2030 ($MILLION)
TABLE 86.SOUTH AFRICA PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER 2020–2030 ($MILLION)
TABLE 87.REST OF LAMEA PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 88.REST OF LAMEA PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020–2030 ($MILLION)
TABLE 89.REST OF LAMEA PHARMACOVIGILANCE OUTSOURCING MARKET, END USER, 2020–2030 ($MILLION)
TABLE 90.LAMEA PHARMACOVIGILANCE OUTSOURCING MARKET, BY TYPE, 2020–2030 ($MILLION)
TABLE 91.LAMEA PHARMACOVIGILANCE OUTSOURCING MARKET, BY SERVICE PROVIDER, 2020–2030 ($MILLION)
TABLE 92.LAMEA PHARMACOVIGILANCE OUTSOURCING MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 93.ACCENTURE PLC.: COMPANY SNAPSHOT
TABLE 94.ACCENTURE PLC.: PRODUCT SEGMENTS
TABLE 95.ACCENTURE PLC.: PRODUCT PORTFOLIO
TABLE 96.BIOCLINICA INC. COMPANY: COMPANY SNAPSHOT
TABLE 97.BIOCLINICA INC.: OPERATING SEGMENTS
TABLE 98.BIOCLINICA INC.: PRODUCT PORTFOLIO
TABLE 99.CAPGEMINI: COMPANY SNAPSHOT
TABLE 100.CAPGEMINI: OPERATING SEGMENTS
TABLE 101.CAPGEMINI: PRODUCT PORTFOLIO
TABLE 102.COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: COMPANY SNAPSHOT
TABLE 103.COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION : OPERATING SEGMENTS
TABLE 104.COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: PRODUCT PORTFOLIO
TABLE 105.ERGOMED PLC: COMPANY SNAPSHOT
TABLE 106.ERGOMED PLC: OPERATING SEGMENTS
TABLE 107.ERGOMED PLC: PRODUCT PORTFOLIO
TABLE 108.GENPACT LIMITED: COMPANY SNAPSHOT
TABLE 109.GENPACT LIMITED: OPERATING SEGMENT
TABLE 110.GENPACT LIMITED: PRODUCT PORTFOLIO
TABLE 111.INTERNATIONAL BUSINESS MACHINES CORPORATION: COMPANY SNAPSHOT
TABLE 112.INTERNATIONAL BUSINESS MACHINES CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 113.INTERNATIONAL BUSINESS MACHINES CORPORATION: PRODUCT PORTFOLIO
TABLE 114.ICON PLC: COMPANY SNAPSHOT
TABLE 115.ICON PLC: PRODUCT PORTFOLIO
TABLE 116.IQVIA INC: COMPANY SNAPSHOT
TABLE 117.IQVIA INC: OPERATING SEGMENTS
TABLE 118.IQVIA INC: PRODUCT PORTFOLIO
TABLE 119.LABCORP DRUG DEVELOPMENT: COMPANY SNAPSHOT
TABLE 120.LABCORP DRUG DEVELOPMENT: OPERATING BUSINESS SEGMENTS
TABLE 121.LABCORP DRUG DEVELOPMENT: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.PHARMACOVIGILANCE OUTSOURCING MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2019–2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019–2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2019–2021
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
FIGURE 10.HIGH INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF ADVERSE DRUG REACTION CAPTURE (ADR) PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 14.COMPARATIVE ANALYSIS OF CASE PROCESSING PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 15.COMPARATIVE ANALYSIS OF REPORTING AND SUBMISSION PHARMACOVIGILANCE OUTSOURCING MARKET,  BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF REPORT PUBLISHING PHARMACOVIGILANCE OUTSOURCING MARKET,  BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 17.COMPARATIVE ANALYSIS OF QUALITY CHECK PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 18.COMPARATIVE ANALYSIS OF RISK MANAGEMENT PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF KNOWLEDGE MANAGEMENT PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 20.COMPARATIVE ANALYSIS OF ENABLING ARCHITECTURE PHARMACOVIGILANCE OUTSOURCING MARKET,  BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 21.COMPARATIVE ANALYSIS OF CONTRACT RESEARCH ORGANIZATIONS PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 22.COMPARATIVE ANALYSIS OF BUSINESS PROCESSING OUTSOURCING PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 23.COMPARATIVE ANALYSIS OF PHARMACEUTICAL INDUSTRY PHARMACOVIGILANCE OUTSOURCING MARKET,  BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 24.COMPARATIVE ANALYSIS OF RESEARCH ORGANIZATION PHARMACOVIGILANCE OUTSOURCING MARKET,  BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 25.COMPARATIVE ANALYSIS OF OTHERS PHARMACOVIGILANCE OUTSOURCING MARKET, BY COUNTRY,  2020 & 2030 ($MILLION)
FIGURE 26.ACCENTURE PLC: NET SALES, 2018–2020 ($MILLION)
FIGURE 27.ACCENTURE PLC: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 28.ACCENTURE PLC: REVENUE SHARE, BY REGION, 2020(%)
FIGURE 29.CAPGEMINI: NET SALES, 2018–2020 ($MILLION)
FIGURE 30.CAPGEMINI: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 31.CAPGEMINI: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 32.COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: NET SALES, 2018–2020 ($MILLION)
FIGURE 33.COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 34.COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION: REVENUE SHARE, BY REGION, 2020(%)
FIGURE 35.ERGOMED PLC: NET SALES, 2018–2020 ($MILLION)
FIGURE 36.ERGOMED PLC: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 37.ERGOMED PLC: REVENUE SHARE, BY REGION, 2020(%)
FIGURE 38.GENPACT LIMITED: NET SALES, 2018–2020 ($MILLION)
FIGURE 39.GENPACT LIMITED: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 40.GENPACT LIMITED: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 41.INTERNATIONAL BUSINESS MACHINES CORPORATION: NET SALES, 2018–2020 ($MILLION
FIGURE 42.INTERNATIONAL BUSINESS MACHINES CORPORATION: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 43.INTERNATIONAL BUSINESS MACHINES CORPORATION: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 44.ICON PLC: NET SALES, 2018–2020 ($MILLION)
FIGURE 45.ICON PLC: REVENUE SHARE, BY REGION, 2020(%)
FIGURE 46.IQVIA HOLDINGS INC: NET SALES, 2018–2020 ($MILLION)
FIGURE 47.IQVIA HOLDINGS INC: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 48.IQVIA HOLDINGS INC: REVENUE SHARE, BY REGION, 2020(%)
FIGURE 49.LABCORP DRUG DEVELOPMENT: NET SALES, 2018–2020 ($MILLION)
FIGURE 50.LABCORP DRUG DEVELOPMENT: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 51.LABCORP DRUG DEVELOPMENT: REVENUE SHARE, BY REGION, 2020 (%)

 
 

Pharmacovigilance outsourcing (PVO) transfers execution of drug safety functions and processes to a third-party provider. These include primary pharmacovigilance activities such as case processing, as well as governance activities such as compliance management.

High profile drug recalls due to safety concerns, increase in trends of outsourcing services, owing to benefits offered by outsourced compliance providers over in-house compliance functions, and increase in adverse drug reactions and drug toxicity boost growth of the market. Furthermore, growth in opportunities in emerging economies create a lucrative opportunity for the market growth. However, risk associated with data security and shortage of skilled professionals for maintaining compliance are expected to hinder growth of the market. 

The case processing segment is expected to remain dominant during the forecast period, owing to continuous increase in cases from various sources resulting from research and development and rise in need to ensure quality of data. Moreover, North America is expected to offer lucrative opportunities to the market during the forecast period, owing to rise in number of drug development activities in the U.S. and presence of major pharma and medical device companies in the region.

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. Pharmacovigilance outsourcing (PVO) transfers the execution of drug safety functions and processes to a third- party provider.

A. PV activities that are generally outsourced include collecting ADR information, case processing activities, development of risk management plans & risk evaluation mitigation strategy as well as creating & submitting aggregate and expedited PV reports.

A. High profile drug recalls due to safety concerns, increase in trends of outsourcing services owing to benefits offered by outsourced compliance providers over in-house compliance functions, and increase in adverse drug reactions and drug toxicity are some factors which boost growth of the market.

A. Top companies such as IBM corporation, Accenture plc., Cognizant, IQVIA holdings, and Labcorp held a high market position in 2020.

A. The market value of pharmacovigilance outsourcing market in 2021 is $2,827.30 million.

A. The total market value of pharmacovigilance outsourcing market is $2,489.10 million in 2020.

A. Case processing segment is the most influencing segment owing to owing to continuous increase in cases from various sources resulting from research and development and rising need for ensuring the quality of data.

A. High profile drug recalls due to safety concerns, increase in trends of outsourcing services owing to benefits offered by outsourced compliance providers over in-house compliance functions, and increase in adverse drug reactions and drug toxicity are some factors which boost growth of the market.

A. Asia-Pacific is expected to experience the highest growth rate during the forecast period, owing toStrict regulations for reporting adverse drug reactions coupled with large number of companies offering pharmacovigilance outsourcing services across the region.

A. The forcast period for pharmacovigilance outsourcing market is 2021 to 2030

Allied Market Research Allied Market Research Allied Market Research
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Pharmacovigilance Outsourcing Market

Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $10,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers